Sanofi (NASDAQ:SNY) Stock Crosses Above 200-Day Moving Average - Here's What Happened

Key Points

• Sanofi shares rose 2.7%, trading above their 200-day moving average of $44.35 and reaching $45.59, with the latest price at $45.55.
• The company exceeded quarterly expectations, reporting EPS of $2.04 versus $1.56 expected and revenue of $17.25 billion, up 16.2% year over year.
• Analyst sentiment remains mixed but leans positive: the stock has an average “Hold” rating and a consensus price target of $49.50, while institutional investors own 14.03% of shares.

Sanofi (NASDAQ:SNY - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $44.35 and traded as high as $45.59. Sanofi shares last traded at $45.55, with a volume of 7,373,102 shares changing hands.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of analyst reports. Wolfe Research assumed coverage on shares of Sanofi in a research report on Friday, October 9th. They issued a "peer perform" rating on the stock. Berenberg Bank reiterated a "buy" rating on shares of Sanofi in a report on Monday, October 5th. UBS Group reissued a "neutral" rating on shares of Sanofi in a research note on Thursday, September 17th. Sanford C. Bernstein restated a "buy" rating on shares of Sanofi in a report on Monday, August 3rd. Finally, DZ Bank restated a "buy" rating on shares of Sanofi in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $49.50.

Sanofi Stock Up 2.7%

The stock's 50-day moving average price is $42.20 and its two-hundred day moving average price is $44.35. The stock has a market capitalization of $110.43 billion, a PE ratio of 22.55, a P/E/G ratio of 1.30 and a beta of 0.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.48. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. During the same period last year, the business earned $2.91 EPS. Sanofi's quarterly revenue was up 16.2% compared to the same quarter last year. As a group, analysts expect that Sanofi will post 5.00 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in shares of Sanofi by 11.0% in the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company's stock worth $456,956,000 after purchasing an additional 940,342 shares in the last quarter. Mondrian Investment Partners LTD increased its position in Sanofi by 2.3% during the 3rd quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company's stock valued at $233,038,000 after buying an additional 129,575 shares in the last quarter. Royal Bank of Canada raised its stake in Sanofi by 17.5% during the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company's stock valued at $152,011,000 after buying an additional 470,882 shares during the last quarter. Regal Partners Ltd raised its stake in Sanofi by 33.2% during the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company's stock valued at $122,639,000 after buying an additional 633,782 shares during the last quarter. Finally, Manning & Napier Advisors LLC boosted its holdings in Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company's stock worth $57,542,000 after acquiring an additional 1,194,141 shares in the last quarter. Institutional investors own 14.03% of the company's stock.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.